



C4X Discovery

A new dimension in drug discovery

Expansion of Team with Strong Biology and Development Expertise

3 September 2015 - C4X Discovery Holdings plc (“C4XD” or “the Company”), a leader in rational drug discovery and design, today announced that it is further strengthening its team with two new management appointments.

Dr Craig Fox joins the Company as Head of Biology and a member of the Senior Management Team. Dr Fox is an experienced biologist having worked on and managed many drug discovery and development projects during the last 18 years, from initial target selection right through to investigating clinical efficacy and safety in Phase II patient studies. Prior to joining C4XD, Dr Fox was Director of Respiratory Research at Pulmagen Therapeutics, a clinical stage company spun-out of Argenta in 2010. Dr Fox also managed several of Pulmagen’s collaborations and partnerships, including those with AstraZeneca, Chiesi, Domantis, Dr Reddy’s, Skyepharma and Teijin Pharma. Dr Fox was part of the Etiologics Team that merged with Argenta Discovery in 2004 and prior to this he worked for Bayer as a Research Scientist.

Dr Clare Murray joins the Company as Project Manager. Dr Murray spent 23 years with AstraZeneca, where she was most recently Associate Director, Bioscience, within the Emerging Innovations Unit. Whilst at AstraZeneca, Dr Murray led biology, pharmacology and clinical development teams up to Phase II across a range of therapeutic areas including respiratory, inflammation, dermatitis and oncology. Dr Murray has spent the last year at the University of Manchester’s Faculty of Medical and Human Sciences with responsibility for managing a portfolio of translational research projects.

“We are delighted to have further strengthened our management team with the addition of these two highly experienced development professionals and qualified biologists,” said Piers Morgan, CEO of C4XD. “Craig and Clare are highly respected, with solid track records of successfully progressing programmes into early stage clinical development in man, and bring a wealth of deep and relevant experience to support the continued development and value enhancement of our pipeline of programmes.”

--ENDS--

For further information please contact:

C4X Discovery Holdings plc

Piers Morgan, CEO

07912 293832

Zeus Capital

Ross Andrews/Dan Bate

0161 831 1512

Dominic Wilson

020 7533 7727

FTI Consulting

Matthew Cole / Ben Atwell / Matthew Moss

020 3727 1000

About C4XD

C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com